James Hoffman, MD, University of Miami Sylvester Cancer Center

Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.

Factors to consider when choosing the optimal treatment approach after the first relapse of multiple myeloma.

James Hoffman, MD, and Joshua Richter, MD, discuss the IKEMA study, the appropriate selection of therapy, and the differences between various options.

Experts in the field of multiple myeloma discuss the BOSTON trial, the study design, and the benefits of using selinexor in a patient after CAR T-cell therapy.

Drs Hoffman and Richter discuss a promising new treatment for patients with relapsed/refractory multiple myeloma who are not eligible for a clinical trial after 4 lines of therapy.

Experts in treating multiple myeloma discuss the trials that led to the approval of selinexor with bortezomib and dexamethasone, and which patient population would benefit from treatment, as well as the dosing, safety, and efficacy.

Key opinion leaders discuss newly approved agents and their impact on treatment decisions for relapsed/refractory multiple myeloma.

Myeloma experts, Drs James Hoffman and Joshua Richter, discuss the factors that increase a patient’s risk of relapse after frontline treatment for multiple myeloma.